Navigation Links
Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
Date:3/24/2008

p>2007 Financial Results

Ardea's 2007 year-end cash balance was $66.2 million, compared to $48.7 million for the 2006 year-end cash balance. The December 31, 2007 cash balance includes net proceeds of $37.2 million from a private placement of common stock in December 2007.

The net loss for the fourth quarter 2007 was $9.1 million, or $0.86 per share, compared to a net loss for the same period in 2006 of $0.5 million, or $0.05 per share. The net loss for the year ended December 31, 2007 was $25.3 million, or $2.55 per share, compared to a net loss for the year ended December 31, 2006 of $0.6 million, or $0.07 per share. The net loss for the quarter and full-year ended December 31, 2007 included non-cash stock-based compensation expense of $0.6 million, or $0.05 per share, and $1.4 million, or $0.14 per share, respectively. The difference between the Company's 2007 and 2006 results reflects the rebuilding of its operations combined with the advancement and expansion of its preclinical and clinical drug development programs.

Revenues for the fourth quarter of 2007 were $0.3 million, compared to zero for the same period in 2006. Revenues for the full-year 2007 were $3.1 million compared to zero for 2006. The increase is due to research performed by the Company as part of a master services agreement with Valeant.

2008 Financial Guidance

On December 31, 2007, the Company had a total of $66.2 million in cash, cash equivalents and short-term investments. Excluding any funds that Ardea may receive from future business development activities, the Company anticipates 2008 net cash usage to be between $45 million and $50 million.

About Ardea Biosciences

Ardea Biosciences, of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have three drug candidates in clinical trials and several
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
2. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
3. Pressure BioSciences, Inc. Announces Move to New Corporate Offices
4. Numira Biosciences Names New Board Member
5. DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
6. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
7. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
8. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
9. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... November 23, 2014 The report, ... 2006 to 2020 - Asia-Pacific” provides quantitative analysis ... market segments: minimally invasive body contouring devices, non-invasive ... analysis includes market size data by revenue and ... following countries: China, Japan, South Korea, Australia and ...
(Date:11/23/2014)... 2014 (HealthDay News) -- The holidays can be a ... overload can trigger major meltdowns, an expert says. ... of circumstances, but when you have children with special ... occupational therapy professor at University of the Sciences in ... best to let your hosts or visitors know what ...
(Date:11/23/2014)... 23, 2014 More than two dozen ... a federal litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), ... Liebhard LLP reports. , A Case List updated ... class of Type 2 diabetes medications referred to as ... District Court, Southern District of California, where a federal ...
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/22/2014)... 2014 A new AlignLife Chiropractic & ... the downtown Greenville area. Dr. Chelsea Sineath, owner and ... to open her own clinic after working in another ... patients. , AlignLife believes that the body can ... focus on chiropractic care and rehabilitation to allow the ...
Breaking Medicine News(10 mins):Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2
... 28 (HealthDay News) -- While the hormone oxytocin makes people ... study shows. Oxytocin -- a naturally occurring hormone that ... an important role in social behavior. Increased levels of the ... overall caring, generosity and trust, but it hasn,t been known ...
... of the most spectacular migrations on Earth is that of ... Acknowledged as one of the wonders of the natural world, ... five-kilometre breeding migration. Now, scientists have discovered the key to ... a team led by the late Professor Steve Morris from ...
... Traumatic brain injury, currently considered a singular event ... is instead the beginning of an ongoing process that ... other diseases and disorders that can reduce life expectancy, ... Branch at Galveston. As such, traumatic brain injury ...
... study not only has confirmed that children who have ... more prone to emotional problems, but many of those ... or peer violence that could exacerbate those issues. ... on top of exposure to disaster had more anxiety, ...
... a small and cheap-to-build unmanned aerial vehicle (UAV) intended ... reduce risks to material and human lives. The seaplane ... plane to fly in severe weather conditions. The resulting ... payload of up to 40 kg. It is equipped ...
... single cochlear implant capable of giving sound in both ears ... of the South of England Cochlear Implant Centre (SOECIC), based ... is an electronic device that can help both adults and ... has two parts: an internal receiver/stimulator package and electrode array, ...
Cached Medicine News:Health News:Oxytocin Increases Trust, Not Gullibility 2Health News:Scientists discover key to Christmas Island's red crab migration 2Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 2Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 3Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 4Health News:Victimized children involved with disasters more likely to have mental health issues 2Health News:Victimized children involved with disasters more likely to have mental health issues 3Health News:Shape-shifting robot plane offers safer alternative for maritime rescue 2Health News:Shape-shifting robot plane offers safer alternative for maritime rescue 3Health News:Southampton to conduct UK's first cochlear implant operation to give sound in both ears 2
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... 20, 2014  RedRick Technologies, a provider of ... room environment guidance, has helped the new Penn ... room, which may also serve as a model ... "In line with the tenets ... Radiology,s Imaging 3.0 ™ initiative, the new ...
(Date:11/21/2014)... CORAL GABLES, Fla. , Nov. 20, 2014 /PRNewswire/ ... working to become the first U.S. commercial producer of ... signed a contract with INVAP to design ... Alachua, Fla. Mo-99 is the parent isotope ... nuclear medicine procedures worldwide. In 2012, Congress passed legislation ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Trust, Inc. (NYSE: BMR ) announced ... with Omeros Corporation (NASDAQ: OMER ) ... Seattle, Washington.  A clinical-stage biopharmaceutical company committed to ... coagulopathies and disorders of the central nervous system, Omeros ...
... Feb. 1, 2012 Novartis announced today that following ... (FDA) has approved an update to the Gleevec ® ... of treatment after surgery for adult patients with KIT ... of recurrence inclusion criteria of the pivotal trial. This ...
Cached Medicine Technology:BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 2BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 3BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 4FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 2FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 3FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 4FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 5FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 6FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 7FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 8
The Synoptiscope(L-2510B) has a wide variety of functions including binocular function diagnosis and treatment....
Inquire...
Security and confidence assured with porous tape; integral deodorizing/venting filter....
Inquire...
Medicine Products: